VP, Digital Strategy
Kevin Silverman is a vice president in the New York office of Ogilvy PR. He is a member of the 360° Digital Influence team, specializing in U.S. Healthcare practices, bringing a unique understanding of social media and the regulatory environment in which our clients work.
He has provided communications support and disease awareness initiatives for some of the world’s leading healthcare companies including 3M, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Dey, GlaxoSmithKline, Merck, Merck Serono, Nestle, Novartis and Pfizer in the areas of rare diseases, pain management, oncology, diabetes, men’s health, respiratory disease, virology and women’s health.
Kevin’s recent work has focused on developing and implementing communications strategies around ethical pharmaceutical product approvals/launches, regional thought leadership, public affairs, crisis/issues management, media relations, advocacy relations and supporting fast moving consumer goods that provide health benefits. These strategies focus on utilizing social media along with more traditional outlets.
Having recently returned from two years in Ogilvy PR’s Sydney office, Kevin has broad experience providing US, Australian, regional and global communications support on behalf of healthcare companies.
Supporting regional and global brands, Kevin has worked to ready next-to-market countries in Europe and Latin America for local approvals, coordinating with overseas Ogilvy PR offices to develop a hub-and-spoke network for PR support. He has also helped plan and implement unbranded disease awareness programs designed to increase consumer awareness and knowledge. This includes the development of two groundbreaking partnerships with Major League Baseball (MLB) and the National Football League (NFL), partnering with leading advocacy groups and supported by pharmaceutical companies.
In addition, Kevin has created and facilitated programs to promote corporate social responsibility and patient access programs on behalf of Merck in the wake of the withdrawal of Vioxx from the U.S. marketplace.
Kevin graduated magna cum laude from New York University with high honors in Communications.